# IFW

## PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Marlon D. Cowart

Serial No.: 10/656,672

Filed: September 5, 2003

For: BENZIMIDAZOLES THAT ARE USEFUL

IN TREATING SEXUAL DYSFUNCTION

Examiner: (not assigned)

Group Art Unit: 1642

Attorney Docket No.: 6789.US.O3

Date: May 10, 2005

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Mailstop: Amendment Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450, on:

Date of Deposit: May 10, 200

Wanda E. Smith

Date

## TRANSMITTAL LETTER

Mailstop: Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is a Supplemental Information Disclosure Statement for Marlon D. Cowart, for BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION, the specification of which was filed on September 5, 2003, and received Serial No. 10/656,672.

Also enclosed are:

Form PTO 1449 (in duplicate) w/4 (four) references

Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES

Phone: (847) 935,4314 FAX: (847) 938-2623

Respectfully submitted,

Marlon D. Cowart

Gabryleda Ferrari-Dileo Registration No. 55,174

Attorney for Applicants

# MAN 12 2005 IN THE UNITE

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/656,672

Filed: September 5, 2003

For: BENZIMIDAZOLES THAT ARE USEFUL

IN TREATING SEXUAL DYSFUNCTION

Examiner: (not assigned)

Group Art Unit: 1642

Attorney Docket No.: 6789.US.O3

Date: May 10, 2005

Certificate of Mailing under 37 CFR §1.8(a): I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being

referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Mailstop: Amendment Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450, on:

Date of Deposit: May 10, 2005

Wanda F Smith

<u>3/10/</u>

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mailstop: Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This supplemental information disclosure statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

The Applicants submit herewith Form PTO 1449 listing the references cited for this Information Disclosure Statement.

The Applicants respectfully request that the Examiner initial next to each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and that a copy of the initialed Form PTO 1449 be returned to Applicants.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.

23492

ABBOTT LABORATORIES

Phone: (847) 935,4314 FAX: (847) 938-2623

Respectfully submitted,

Marlon D. Cowart

Gabryleda Ferrari-Dileo Registration No. P-55,174 Attorney for Applicants MAY 1 2 2005

**DATE: May 10, 2005** 

SHEET \_1\_ of \_1\_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified)	U.S. DEPARTMENTOE COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6789.US.O3	SERIAL NO. 10/656,672	
	•	0703703700	10.000,0.2	
	INFORMATION DISCLOSURE	APPLICANT(S)		
	STATEMENT BY APPLICANT	M. D. Cowart, et al.		
		FILING DATE	GROUP	
	(Use several sheets if necessary)	September 5, 2003	1642	
(37 CFR 1.98 (b))			<b>1</b> •	

#### **U.S.PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
						(45.119)

### FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC- ATION	COUNTRY OR		SUB	TRANS- LATION	
		DATE	PATENT OFFICE	CLASS	CLASS	YES	NO
B1	94/22839	13.10.94	WO				
				,			

#### OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977)
C2	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)
C3	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6) – substituted benzimidazoles," Bull. Haffkine Inst. 6(2):62-64 (1978)
C4	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)

EXAMINER DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)